A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
2. Life expectancy >=3 months, in the investigator's judgment
3. Adequate hematologic and end-organ function
4. Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care
5. Measurable disease per RECIST v1.1
6. Tumor specimen availability, for certain cohorts

Exclusion Criteria:

1. Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to C1D1, with certain exceptions
2. Active hepatitis B or C
3. Active tuberculosis
4. Positive test for HIV infection
5. Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion
6. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
7. Active or history of autoimmune disease
8. Prior allogeneic stem cell or organ transplantation
9. Uncontrolled tumor-related pain
10. Significant cardiovascular disease

Other protocol-defined inclusion/exclusion criteria may apply.